Presenter Disclosure Information

1:30 – 2:45pm

The following relationships exist related to this presentation:

Current Concepts in The Management of ASCVD: What New Prevention Evidence Tells Us

► Gregg C. Fonarow, MD, FACC, FAHA: Consultant for Medtronic; Novartis; Johnson & Johnson; Amgen. Grant support from NIH/AHRQ. ► James de Lemos, MD: Contracted research for Abbott Diagnostics. Consultant for Amgen and Diadexus. ► Michael J Bloch, MD, FACP, FASH, FNLA, FSVM: Speakers bureau for Arbor; Medtronic; Lundbeck. Grant support from AstraZeneca. Consultant for Takeda, Amgen, Janssen, and Lundbeck.

SPEAKERS Gregg C. Fonarow, MD, FACC, FAHA James de Lemos, MD Michael J. Bloch, MD, FACP, FASH, FNLA, FSVM

Off-Label/Investigational Discussion ► In accordance with pmiCME policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations.

Current Concepts in Management of ASCVD. What New Prevention Evidence Tells Us Gregg C. Fonarow, MD James de Lemos, MD Michael J. Bloch, MD April 10, 2015

ATP III Update 2004: LDL-C Goals and Cut-points for Therapy in Different Risk Categories Risk Category

LDL-C Goal

Initiate TLC

Consider Drug Therapy

Very High risk: ACS, or CHD w/ DM, mult CRF

70 mg/dL

High risk: CHD or CHD risk equivalents (10-year risk >20%)